Most Read Articles
Roshini Claire Anthony, Yesterday

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 5 days ago
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
17 May 2018
A study examining the validity of baseline cardiac screening for left ventricular ejection fraction (EF) has found that only two (1.1 percent) of the screened patients have an abnormal EF (<50 percent). These patients have received doxorubicin (anthracycline) chemotherapy despite a compromised EF.
Yesterday
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.

Denosumab, bisphosphonates improve BMD in men with prostate cancer

16 Aug 2017

Both denosumab and bisphosphonates enhance bone mineral density (BMD) in men with nonmetastatic prostate cancer who are receiving androgen deprivation therapy (ADT), according to a systematic review and meta-analysis. In addition, denosumab lowers the risk for radiographic vertebral fractures.

Researchers searched Medline (1946 to 19 January 2017), Embase (1980 to 18 January 2017) and the Cochrane Database of Systematic Reviews (19 January 2017) for randomized trials and systematic reviews of trials that were published in English; involved men with nonmetastatic prostate cancer; and compared bone-targeted therapies with placebo, usual care or other active treatments.

In total, there were two systematic reviews and 28 reports of 27 trials that met the inclusion criteria. All trials centred on men with nonmetastatic prostate cancer who were initiating or continuing ADT.

Although no trial was adequately powered to detect reduction in fractures, bisphosphonates were effective in improving BMD. Denosumab increased BMD and reduced the incidence of new radiographic vertebral fractures in one high-quality trial.

There were no trials comparing calcium or vitamin D vs placebo. In three intervention trials, there was no statistically significant difference seen in change in BMD between exercise and usual care.

These findings should be considered in light of several limitations. First, most trials were of moderate quality. Second, only two randomized controlled trials were designed to assess fracture outcomes. Finally, there was no study that examined the potential harms of treatments.

Thus, “more trials studying fracture outcomes are needed in this population,” according to researchers, adding that bone health is a significant concern in men with prostate cancer.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, Yesterday

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 5 days ago
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
17 May 2018
A study examining the validity of baseline cardiac screening for left ventricular ejection fraction (EF) has found that only two (1.1 percent) of the screened patients have an abnormal EF (<50 percent). These patients have received doxorubicin (anthracycline) chemotherapy despite a compromised EF.
Yesterday
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.